Our findings indicate that a chicken egg bioreactor system can overcome these bottlenecks, and thereby contribute to the future development of recombinant ADPN as an effective therapeutic agent for various metabolic diseases. This evidence concerns the gene ADIPOQ and Other metabolic disease.